Uncovering the Secrets of F Cells: The Next Chapter in Sickle Cell Research at King’s
Following the revolutionary breakthrough in gene-editing treatments for sickle cell disease, research at King’s College London continues to push boundaries in the search for a universal and affordable cure. While the introduction of CRISPR/Cas9 therapies marked a significant milestone, the journey is far from over. Our understanding of how blood cells are made – and how to harness their full healing potential – remains incomplete.
At the heart of current investigations lies a fascinating and elusive target: the F cell.
Why F Cells Matter
F cells are a special type of red blood cell that produce foetal haemoglobin, which is unaffected by the sickle cell mutation. When present in higher numbers, F cells can greatly reduce the severity of sickle cell disease symptoms. Some patients naturally produce more of these protective cells, resulting in milder forms of the disease. The goal? To understand how F cells develop – and how we can safely stimulate their production in all patients.
Cutting-Edge Research in Action
In the Sickle Cell and Globin Genetics Lab at King’s, Research Assistant Helen Rooks is leading efforts to uncover the origins of F cells. She is culturing stem cells from the blood of healthy volunteers, carefully studying the moment these elusive cells emerge. This painstaking work involves analysing thousands of individual cells, each offering a potential clue in the larger puzzle.
Helen is supported by a visiting researcher from China, whose expertise in sample processing and cell culture is accelerating progress. To manage the vast amount of data being generated, the team has also welcomed a dedicated Master’s student who is learning advanced software tools to help unlock new insights.
This is no ordinary research – it’s experimental, exploratory, and deeply collaborative. As Helen puts it, “None of what we are doing is ‘run-of-the-mill’. We’re all learning as we go, but each step is taking us closer to understanding how to harness F cells to improve patients’ lives.”
Partnering for Innovation: MiNA Therapeutics
In a promising development, the lab has now partnered with MiNA Therapeutics, a pioneering London-based biotech company. Together, they’re exploring novel ways to stimulate F cell production – potentially offering new, accessible therapies for patients worldwide.
The Role of LIBRA in Driving Progress
Behind the scenes, LIBRA’s support has been instrumental in making this work possible. By helping to link these research strands into a cohesive, strategic programme, LIBRA enables the team at King’s to pursue vital experiments and gather the data needed to advance the field.
This research doesn’t just benefit the UK – it has global implications, particularly for countries where access to expensive gene therapies is limited. An affordable, F cell-based approach could transform the treatment landscape for millions.
Join Us in the Search for a Cure
Every breakthrough starts with a question. With your continued support, LIBRA can help provide the tools, funding, and freedom researchers need to keep asking – and answering – the most important ones.
Whether you’re donating, fundraising, or spreading the word, you’re helping to bring hope, healing, and change to those living with sickle cell disease and other blood disorders.
Support this vital work today.
Back to all posts